V. A. Seligman, R. F. Lum, and J. L. Olson, Demographic differences in the development of lupus nephritis: a retrospective analysis, Am J Med, vol.112, pp.726-729, 2002.

R. Cervera, M. A. Khamashta, and J. Font, Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients, Medicine, vol.82, pp.299-308, 2003.

J. G. Hanly, A. G. O'keeffe, and L. Su, The frequency and outcome of lupus nephritis: results from an international inception cohort study, Rheumatology (Oxford), vol.55, pp.252-262, 2016.

A. Duarte-garcía, E. Barr, and L. S. Magder, Predictors of incident proteinuria among patients with SLE, Lupus Sci Med, vol.4, p.200, 2017.

B. Artim-esen, E. Çene, and Y. ?ahinkaya, Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center, J Rheumatol, vol.41, pp.1304-1310, 2014.

C. Siegert, M. Daha, and M. L. Westedt, IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus, J Rheumatol, vol.18, pp.230-234, 1991.

D. J. Birmingham, J. E. Bitter, and E. G. Ndukwe, Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare, CJASN, vol.11, pp.47-53, 2016.

G. K. Bertsias and D. T. Boumpas, Lupus nephritis-winning a few battles but not the war, Nature Rev Rheumatology, vol.7, pp.441-442, 2011.

N. Maroz and M. S. Segal, Lupus Nephritis and End-stage Kidney Disease, Am J Med Sci, vol.346, pp.319-323, 2013.

M. Adler, S. Chambers, and C. Edwards, An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period, Rheumatology, vol.45, pp.1144-1147, 2006.

D. J. Sexton, S. Reule, and C. Solid, ESRD From Lupus Nephritis in the United States, CJASN, vol.10, pp.251-259, 1995.

B. I. Freedman, C. D. Langefeld, and K. K. Andringa, End-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1, Arthritis Rheumatol, vol.66, pp.390-396, 2014.

K. H. Costenbader, A. Desai, and G. S. Alarcón, Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from, Arthritis & Rheumatism, vol.63, pp.1681-1688, 1995.

C. Specker, A. Becker, and H. J. Lakomek,

, Z Rheumatol, vol.53, pp.339-345, 1994.

A. L. Resende, S. M. Titan, and R. T. Barros, Worse renal outcome of lupus nephritis in male patients: a case-control study, Lupus, vol.20, pp.561-567, 2011.

T. C. Tan, H. Fang, and L. S. Magder, Differences between Male and Female Systemic Lupus Erythematosus in a Multiethnic Population, J Rheumatol, vol.39, pp.759-769, 2012.

C. Fiehn, Y. Hajjar, and K. Mueller, Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment, Ann Rheum Dis, vol.62, pp.435-439, 2003.

M. Faurschou, H. Starklint, and P. Halberg, Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure, J Rheumatol, vol.33, pp.1563-1569, 2006.

D. J. Park, J. H. Kang, and J. W. Lee, Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis, Lupus, vol.26, pp.1139-1148, 2017.

A. Devlin, S. S. Waikar, and D. H. Solomon, Variation in initial kidney replacement therapy for endstage renal disease due to lupus nephritis in the United States, Arthritis Care & Research, vol.63, pp.1642-1653, 2011.

B. Levy, C. Couchoud, and J. Rougier, Outcome of patients with systemic lupus erythematosus on chronic dialysis: an observational study of incident patients of the French National Registry, Lupus, vol.24, pp.1111-1121, 2002.

A. Mathian, L. Arnaud, and Z. Amoura, Physiopathologie du lupus systémique : le point en, La Revue de Médecine Interne, vol.35, pp.503-511, 2014.

E. S. Mortensen and O. P. Rekvig, Nephritogenic Potential of Anti-DNA Antibodies against Necrotic Nucleosomes, JASN, vol.20, pp.696-704, 2009.

E. Villanueva, S. Yalavarthi, and C. C. Berthier, Netting Neutrophils Induce Endothelial Damage, Infiltrate Tissues, and Expose Immunostimulatory Molecules in Systemic Lupus Erythematosus, J Immunol, vol.187, pp.538-552, 2011.

A. Bergtold, A. Gavhane, D. 'agati, and V. , FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis, J Immunol, vol.177, pp.7287-7295, 2006.

M. Rathi, A. Goyal, and A. Jaryal, Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis, Kidney Int, vol.89, pp.235-242, 2016.

H. Sekine, P. Ruiz, and G. S. Gilkeson, The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition, Mol Immunol, vol.49, pp.317-323, 2011.

E. A. Leadbetter, I. R. Rifkin, and A. M. Hohlbaum, Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors, Nature, vol.416, pp.603-607, 2002.

A. Davidson, What is damaging the kidney in lupus nephritis?, Nat Revi Rheumatol, vol.12, pp.143-153, 2016.

A. Migliorini, M. L. Angelotti, and S. R. Mulay, The Antiviral Cytokines IFN-? and IFN-? Modulate Parietal Epithelial Cells and Promote Podocyte Loss: Implications for IFN Toxicity, Viral Glomerulonephritis, and Glomerular Regeneration, Am J Pathol, vol.183, pp.431-440, 2013.

A. Chang, S. G. Henderson, and D. Brandt, Situ B Cell-Mediated Immune Responses and Tubulointerstitial Inflammation in Human Lupus Nephritis, J Immunol, vol.186, pp.1849-1860, 2011.

B. Smeets, C. Kuppe, and E. Sicking, Parietal Epithelial Cells Participate in the Formation of Sclerotic Lesions in Focal Segmental Glomerulosclerosis, JASN, vol.22, pp.1262-1274, 2011.

. Amoura, , 2017.

J. J. Weening, . Vd, and M. M. Schwartz, The classification of glomerulonephritis in systemic lupus erythematosus revisited, Kidney Int, vol.65, pp.521-530, 2004.

I. M. Bajema, S. Wilhelmus, and C. E. Alpers, Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices, Kidney Int, vol.93, pp.789-796, 2018.

S. M. Korbet, E. J. Lewis, and M. M. Schwartz, Factors predictive of outcome in severe lupus nephritis, Am J Kidney Dis, vol.35, pp.904-914, 2000.

Y. E. Chen, S. M. Korbet, and R. S. Katz, Value of a Complete or Partial Remission in Severe Lupus Nephritis, CJASN, vol.3, pp.46-53, 2008.

F. A. Houssiau, C. Vasconcelos, D. Cruz, and D. , Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide: Immunosuppressive Therapy in Lupus Nephritis, Arthritis & Rheumatism, vol.46, pp.2121-2131, 2002.

G. B. Appel, G. Contreras, and M. A. Dooley, Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis, JASN, vol.20, pp.1103-1112, 2009.

B. H. Rovin, R. Furie, and K. Latinis, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study, Arthritis & Rheumatism, vol.64, pp.1215-1226, 2012.

Z. Liu, H. Zhang, and Z. Liu, Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial, Ann Int Med, vol.162, p.18, 2015.

C. C. Mok, K. Y. Ying, and C. W. Yim, Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up, Ann Rheum Dis, vol.75, pp.30-36, 2016.

C. C. Mok, K. Y. Ying, and W. L. Ng, Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide, Am J Med, vol.119, pp.355-380, 2006.

M. A. Dooley, Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis, N Engl j Med, p.10, 2011.

H. A. Austin, G. G. Illei, and M. J. Braun, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy, JASN, vol.20, pp.901-911, 2009.

G. Wu, H. Liu, and R. Leng, Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis, Autoimmunity Reviews, vol.15, pp.22-37, 2016.

G. Thomas, J. Mancini, and N. Jourde-chiche, Mortality Associated With Systemic Lupus Erythematosus in France Assessed by Multiple-Cause-of-Death Analysis: Mortality and Systemic Lupus Erythematosus, Arthritis & Rheumatology, vol.66, pp.2503-2511, 2014.

M. J. Roman, M. D. Lockshin, and M. K. Crow, Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus, New Engl J Med, vol.8, 2003.

Y. Asanuma, A. Oeser, and A. K. Shintani, Premature Coronary-Artery Atherosclerosis in Systemic Lupus Erythematosus, New Engl J Med, vol.349, pp.2407-2415, 2003.

L. S. Magder and M. Petri, Incidence of and Risk Factors for Adverse Cardiovascular Events Among Patients With Systemic Lupus Erythematosus, Am J Epidemiol, vol.176, pp.708-719, 2012.

M. Iudici, S. Fasano, G. Falcone, and L. , Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study, Rheumatology, vol.55, pp.1623-1630, 2016.

A. Fanouriakis, M. Kostopoulou, and A. Alunno, 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus, Ann Rheum Dis, vol.78, pp.736-745, 2019.

H. C. Nossent, T. J. Swaak, and J. H. Berden, Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE, Am J Med, vol.89, pp.169-174, 1990.

J. S. Cheigh, H. Kim, and K. H. Stenzel, Systemic Lupus Erythematosus in Patients with End-Stage Renal Disease: Long-Term Follow-Up on the Prognosis of Patients and the Evolution of Lupus Activity, Am J Kidney Dis, vol.16, pp.189-195, 1990.

C. F. Mojcik and J. H. Kuppel, End-stage renal disease and systemic lupus erythematosus, Am J Med, vol.101, pp.100-107, 1996.

I. N. Bruce, D. C. Hallett, and D. D. Gladman, Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy, J Rheumatol, vol.26, pp.1490-1494, 1999.

N. K. Krane, K. Burjak, and M. Archie, Persistent lupus activity in end-stage renal disease, Am J Kidney Dis, vol.33, pp.872-879, 1999.

F. M. Ribeiro, M. Leite, and G. C. Velarde, Activity of Systemic Lupus Erythematosus in End-Stage Renal Disease Patients: Study in a Brazilian Cohort, Am J Nephrol, vol.25, pp.596-603, 2005.

D. Yap, C. Tang, and M. Ma, Survival analysis and causes of mortality in patients with lupus nephritis, Nephrol Dial Transplant, vol.27, pp.3248-3254, 2012.

S. Bernatsky, J. Boivin, and L. Joseph, Mortality in systemic lupus erythematosus, Arthritis Rheum, vol.54, pp.2550-2557, 2006.

R. Moe, S. E. Molberg, Ø. Strøm, and E. H. , Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort, Lupus, vol.28, pp.818-825, 2019.

H. Chen, J. Wang, and C. Chou, Predictors of Longterm Mortality in Patients with and without Systemic Lupus Erythematosus on Maintenance Dialysis: A Comparative Study, J Rheumatol, vol.38, pp.2390-2394, 2011.

J. J. Sim, S. K. Bhandari, and M. Batech, End-Stage Renal Disease and Mortality Outcomes Across Different Glomerulonephropathies in a Large Diverse US Population, Mayo Clinic Proc, vol.93, pp.167-178, 2018.

M. M. Ward, Cardiovascular and cerebrovascular morbidity and mortality among women with endstage renal disease attributable to lupus nephritis, Am J Kidney Dis, vol.36, pp.516-525, 2000.

R. Nee, J. Martinez-osorio, and C. M. Yuan, Survival Disparity of African American Versus Non-African American Patients With ESRD Due to SLE, Am J Kidney Dis, vol.66, pp.630-637, 2015.

F. M. Ribeiro, C. L. Fabris, and I. Bendet, Survival of lupus patients on dialysis: a Brazilian cohort, Rheumatology, vol.52, pp.494-500, 2013.

C. Weng, C. Hsu, and C. Yu, Peritoneal dialysis and hemodialysis in systemic lupus erythematosus patients: comparison of clinical outcomes, Kidney Blood Press Res, vol.32, pp.451-456, 2009.

G. Contreras, J. Pagan, and R. Chokshi, Comparison of Mortality of ESRD Patients with Lupus by Initial Dialysis Modality, CJASN, vol.9, pp.1949-1956, 2014.

A. Jorge, Z. S. Wallace, and N. Lu, Renal Transplantation and Survival Among Patients With Lupus Nephritis: A Cohort Study, Ann Intern Med, 2019.

M. M. Ward, Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis, Kidney Int, vol.57, pp.2136-2143, 2000.

G. Moroni, F. Tantardini, and B. Gallelli, The Long-Term Prognosis of Renal Transplantation in Patients With Lupus Nephritis, Am J Kid Dis, vol.45, pp.903-911, 2005.

S. Bunnapradist, P. Chung, and A. Peng, Outcomes of Renal Transplantation for Recipients With Lupus Nephritis: Analysis of the Organ Procurement and Transplantation Network Database, Transplantation, vol.82, pp.612-618, 2006.

H. Tang, M. Chelamcharla, and B. C. Baird, Factors affecting kidney-transplant outcome in recipients with lupus nephritis, Clinical Transplantation, vol.22, pp.263-272, 2008.

J. H. Stone, W. Amend, and L. A. Criswell, Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls, Arthritis & Rheumatism, vol.41, pp.1438-1445, 1998.

G. K. Bertsias, M. Tektonidou, and Z. Amoura, Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis, Ann Rheum Dis, vol.71, pp.1771-1782, 2012.

S. Baracat, A. L. Ribeiro-alves, M. Alves-filho, and G. , Systemic Lupus Erythematosus After Renal Transplantation: Is Complement a Good Marker for Graft Survival?, Transplant Proc, vol.40, pp.746-748, 2008.

A. Goldfarb-rumyantzev, J. F. Hurdle, and J. Scandling, Duration of end-stage renal disease and kidney transplant outcome, Nephrol Dial Transplant, vol.20, pp.167-175, 2005.

L. C. Plantinga, R. E. Patzer, and C. Drenkard, Association of Time to Kidney Transplantation with Graft Failure among U.S. Patients with End-Stage Renal Disease Due to Lupus Nephritis, Arthritis Care Res (Hoboken), vol.67, pp.571-581, 2015.

M. Chung, Y. Shu, and K. , Influence of Pretransplantation Dialysis Time and Lupus Activity on Outcome of Kidney Transplantation in Systemic Lupus Erythematosus, Transplant Proc, vol.46, pp.336-338, 2014.

A. Naveed, C. Nilubol, and J. K. Melancon, Preemptive Kidney Transplantation in Systemic Lupus Erythematosus, Transplant Proc, vol.43, pp.3713-3714, 2011.

G. Contreras, A. Mattiazzi, and G. Guerra, Recurrence of Lupus Nephritis after Kidney Transplantation, JASN, vol.21, pp.1200-1207, 2010.

S. Goral, C. Ynares, and S. B. Shappell, Recurrent lupus nephritis in renal transplant recipients revisited: It is not rare1, Transplantation, vol.75, pp.651-656, 2003.

G. E. Norby, E. H. Strom, and K. Midtvedt, Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study, Ann RHeum Dis, vol.69, pp.1484-1487, 2010.

P. I. Burgos, E. L. Perkins, and G. J. Pons-estel, Risk Factors and Impact of Recurrent Lupus Nephritis in Transplanted Patients with Systemic Lupus Erythematosus: Data from a Single US Institution, Arthritis Rheum, vol.60, pp.2757-2766, 2009.

, Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to know? Where do we go from here? Special report from the National Kidney Foundation Task Force on Cardiovascular Disease, Am J Kidney Dis, vol.32, pp.1-199, 1998.

G. C. Oniscu, H. Brown, and J. Forsythe, How great is the survival advantage of transplantation over dialysis in elderly patients?, Nephrol Dial Transplant, vol.19, pp.945-951, 2004.

R. Foley, P. Parfrey, and M. Sarnak, Clinical epidemiology of cardiovascular disease in chronic renal disease, Am J Kid Dis, vol.32, pp.112-119, 1998.

S. Methven, R. Steenkamp, and S. Fraser, UK Renal Registry 19th Annual Report: Chapter 5 Survival and Causes of Death in UK Adult Patients on Renal Replacement Therapy in 2015: National and Centre-specific Analyses, Nephron, vol.137, pp.117-150, 2017.

P. A. Devine, A. E. Courtney, and A. P. Maxwell, Cardiovascular risk in renal transplant recipients, J Nephrol, vol.32, pp.389-399, 2019.

G. E. Norby, T. Leivestad, and G. Mjøen, Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation, Arthritis & Rheumatism, vol.63, pp.733-737, 2011.

J. C. Ramirez-sandoval, H. Chavez-chavez, and M. Wagner, Long-term survival of kidney grafts in lupus nephritis: a Mexican cohort, Lupus, vol.27, pp.1303-1311, 2018.

R. Cervera, R. Serrano, and G. J. Pons-estel, Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients, Ann Rheum Dis, vol.74, pp.1011-1018, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01939724

J. H. Stone, W. Amend, and L. A. Criswell, Antiphospholipid antibody syndrome in renal transplantation: Occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus, Am J Kidney Dis, vol.34, pp.1040-1047, 1999.

J. M. Morales, J. A. Martinez-flores, and M. Serrano, Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to ?2-Glycoprotein I, JASN, vol.26, pp.735-745, 2015.

J. M. Morales, M. Serrano, and J. A. Martínez-flores, The Presence of Pretransplant Antiphospholipid Antibodies IgA Anti-?-2-Glycoprotein I as a Predictor of Graft Thrombosis After Renal Transplantation, Transplantation, vol.101, pp.597-607, 2017.

S. Miyakis, M. D. Lockshin, and T. Atsumi, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, vol.4, pp.295-306, 2006.

F. Bienaimé, C. Legendre, and F. Terzi, Antiphospholipid syndrome and kidney disease, Kidney Int, vol.91, pp.34-44, 2017.

G. Canaud, F. Bienaimé, and L. Noël, Severe Vascular Lesions and Poor Functional Outcome in Kidney Transplant Recipients with Lupus Anticoagulant Antibodies: APS-Nephropathy Involving Renal Transplant, Am j Transplant, vol.10, pp.2051-2060, 2010.

A. Ruffatti, P. Marson, and M. Valente, Plasma exchange in a patient with primary antiphospholipid syndrome undergoing kidney transplantation, Transplant Int, vol.20, pp.475-477, 2007.

G. Canaud, N. Kamar, and D. Anglicheau, Eculizumab Improves Posttransplant Thrombotic Microangiopathy Due to Antiphospholipid Syndrome Recurrence but Fails to Prevent Chronic Vascular Changes, Am J Transplant, vol.13, pp.2179-2185, 2013.

M. G. Tektonidou, A. Dasgupta, and M. M. Ward, Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, A Systematic Review and Bayesian Meta-Analysis. Arthritis & Rheumatology, vol.68, pp.1432-1441, 1971.

T. V. Vu and A. Escalante, A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease, J Rheumatol, vol.26, pp.2595-2601, 1999.

S. Sule, B. Fivush, and A. Neu, Increased hospitalizations and death in patients with ESRD secondary to lupus, Lupus, vol.21, pp.1208-1213, 2012.

E. S. Park, S. S. Ahn, and S. M. Jung, Renal outcome after kidney-transplantation in Korean patients with lupus nephritis, Lupus, vol.27, pp.461-467, 2018.

T. Yu, Y. Chen, and J. Lan, Renal outcome and evolution of disease activity in Chinese lupus patients after renal transplantation, Lupus, vol.17, pp.687-694, 2008.

J. Naranjo-escobar, E. Manzi, and J. G. Posada, Kidney transplantation for end-stage renal disease in lupus nephritis, a very safe procedure: a single Latin American transplant center experience, Lupus, vol.26, pp.1157-1165, 2017.

J. Deegens, M. A. Artz, and A. J. Hoitsma, Outcome of renal transplantation in patients with systemic lupus erythematosus, Transplant Int, vol.16, pp.411-418, 2003.

J. Go??biewska, A. D?bska-?lizie?, and B. Bu??o-piontecka, Outcomes in Renal Transplant Recipients With Lupus Nephritis-A Single-Center Experience and Review of the Literature, Transplant Proc, vol.48, pp.1489-1493, 2016.

P. Grimbert, J. Frappier, and J. Bedrossian, Long term outcome of kidney transplantation in patients with systemic lupus erythematosus: A Multicenter Study, Transplantation, vol.66, pp.1000-1003, 1998.

M. A. Lim, J. Kohli, and R. D. Bloom, Immunosuppression for kidney transplantation: Where are we now and where are we going?, Transplant Reviews, vol.31, pp.10-17, 2017.

G. E. Norby, A. Gunther, and G. Mjoen, Prevalence and risk factors for coronary artery calcification following kidney transplantation for systemic lupus erythematosus, Rheumatology, vol.50, pp.1659-1664, 2011.

S. Manzi, E. N. Meilahn, and J. E. Rairie, Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study, Am J Epidemiol, vol.145, pp.408-415, 1997.

A. E. Hak, E. W. Karlson, and D. Feskanich, Systemic lupus erythematosus and risk of cardiovascular disease Results from the Nurses' Health Study, Arthritis Rheum, vol.61, pp.1396-1402, 2009.

A. Jorge, Z. S. Wallace, and N. Lu, Renal Transplantation and Survival Among Patients With Lupus Nephritis: A Cohort Study, Ann Intern Med, vol.170, p.240, 2019.

B. L. Kasiske, Epidemiology of cardiovascular disease after renal transplantation, Transplantation, vol.72, pp.5-8, 2001.

M. Delville, L. Sabbah, and D. Girard, Prevalence and Predictors of Early Cardiovascular Events after Kidney Transplantation: Evaluation of Pre-Transplant Cardiovascular Work-Up, PLOS ONE, vol.10, p.131237, 2015.

J. Neale and A. C. Smith, Cardiovascular risk factors following renal transplant, World J Transplant, vol.5, pp.183-195, 2015.

L. Wei, T. M. Macdonald, and B. R. Walker, Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease, Ann Intern Med, vol.141, pp.764-770, 2004.

L. Fardet and B. Fève, Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events, Drugs, vol.74, pp.1731-1745, 2014.

M. Petri, B. Bechtel, and G. Dennis, Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel, Lupus, vol.23, pp.1006-1013, 2014.

N. Lam, M. V. Ghetu, and M. L. Bieniek, Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management, Am Fam Physician, vol.94, pp.284-294, 2016.

A. C. Gulanikar, P. Belitsky, and A. S. Macdonald, Randomized controlled trial of steroids versus no steroids in stable cyclosporine-treated renal graft recipients, Transplant Proc, vol.23, pp.990-991, 1991.

S. Vítko, M. Klinger, and K. Salmela, Two Corticosteroid-Free Regimens-Tacrolimus Monotherapy after Basiliximab Administration and Tacrolimus/Mycophenolate Mofetil-in Comparison with a Standard Triple Regimen in Renal Transplantation: Results of the Atlas Study, Transplantation, vol.80, pp.1734-1741, 2005.

A. H. Rike, G. Mogilishetty, and R. R. Alloway, Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids, Clin Transplant, vol.22, pp.229-235, 2008.

B. K. Krämer, M. Klinger, and ?. Vítko, Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial, Transplantation, vol.94, pp.492-498, 2012.

C. Ponticelli, M. Carmellini, and G. Tisone, A randomized trial of everolimus and low-dose cyclosporine in renal transplantation: with or without steroids?, Transplant Proc, vol.46, pp.3375-3382, 2014.

M. C. Haller, A. Royuela, and E. V. Nagler, Steroid avoidance or withdrawal for kidney transplant recipients, Cochr Dat Syst Rev, 2016.

K. Manger, M. Kusus, and C. Forster, Factors associated with coronary artery calcification in young female patients with SLE, Ann Rheum Dis, vol.62, pp.846-850, 2003.

A. N. Kiani, W. S. Post, and L. S. Magder, Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus, Rheumatology (Oxford), vol.50, pp.2071-2079, 2011.

C. S. Oliveira, I. Oliveira, and A. Bacchiega, Renal transplantation in lupus nephritis: a Brazilian cohort, Lupus, vol.21, pp.570-574, 2012.

J. F. Nieto-ríos, L. M. Serna-higuita, and S. A. Builes-rodriguez, Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy, Colomb Med (Cali), vol.47, pp.51-58

L. Azevedo, J. Romao, and D. Malheiros, Renal transplantation in systemic lupus erythematosus. A case control study of 45 patients, Nephrol Dial Transplant, vol.13, pp.2894-2898, 1998.

E. Ntatsaki, A. Velo-garcia, and V. S. Vassiliou, Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis, Clin Rheumatol, vol.37, pp.2399-2404, 2018.

P. I. Terasaki, V. D. Mottironi, and E. V. Barnett, Cytotoxins in Disease, New Engl J Med, vol.283, pp.724-728, 1970.

V. Jucaud, M. H. Ravindranath, and P. I. Terasaki, Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies: HLA-F IgG during the clinical course of SLE, Clinical & Experimental Immunology, vol.183, pp.326-340, 2016.

H. Tozkir, O. N. Pamuk, and J. Duymaz, Increased frequency of class I and II anti-human leukocyte antigen antibodies in systemic lupus erythematosus and scleroderma and associated factors: a comparative study, Int J Rheum Dis, vol.19, pp.1304-1309, 2016.

M. M. O'shaughnessy, S. Liu, and M. E. Montez-rath, Kidney Transplantation Outcomes across GN Subtypes in the United States, JASN, vol.28, pp.632-644, 2017.

E. J. Filippone and J. L. Farber, Humoral Immune Response and Allograft Function in Kidney Transplantation, Am J Kid Dis, vol.66, pp.337-347, 2015.

E. Cairoli, C. Sanchez-marcos, and G. Espinosa, Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre, Biomed Res Int, pp.1-7, 2014.

, Serment d'Hippocrate

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux. Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité. J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité. Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré et méprisé si j'y manque